Empowering your fight against breast cancer with PERJETA

A diagnosis of HER2-positive metastatic breast cancer can be overwhelming. Your healthcare team may have given you a lot of new information to understand. If you’ve been prescribed PERJETA as part of your treatment, then you’ve come to the right place to start learning more.

What are the most serious side effects of PERJETA?

Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects.

PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).

Please refer to the full Prescribing Information for more information on these serious side effects.

PERJETA could make treatment stronger 

Results of a clinical study called CLEOPATRA, which studied PERJETA plus Herceptin (trastuzumab) and docetaxel, have shown that:

PERJETA is proven to help control cancer growth

  • Adding PERJETA to Herceptin and docetaxel increased the time that people lived without their cancer growing or spreading by an average of 50%, compared with people who took Herceptin and docetaxel alone

PERJETA increased the time people lived without their cancer 50%

PERJETA helped people live longer

  • On average, people who were given PERJETA, Herceptin, and docetaxel lived longer than people given only Herceptin and docetaxel

PERJETA is proven to shrink tumors

  • 80% of people taking the PERJETA combination had their tumors shrink, compared with 69% of people taking Herceptin and docetaxel alone
  • People who had their tumors shrink maintained this response, on average, for 62% longer on the PERJETA combination compared with people taking only Herceptin and docetaxel (20.2 months vs 12.5 months)

What are the most serious side effects of PERJETA?

Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects.

PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).

Please see additional select Important Safety Information throughout, and the accompanying full Prescribing Information including most serious side effects.

PERJETA is taken together with Herceptin, another HER2 therapy

PERJETA is a targeted therapy used as part of a first-line HER2-positive metastatic breast cancer treatment plan. You should know that this treatment plan includes Herceptin and docetaxel, a type of chemotherapy. PERJETA and Herceptin both target HER2 but are believed to work in complementary ways. The combination may increase death of cancer cells.

Most common side effects seen with PERJETA combination therapy

PERJETA is given together with Herceptin and docetaxel. Side effects can occur with this treatment plan. Not all people have serious side effects; however, side effects with PERJETA therapy are common. It is important to know what side effects may happen and what symptoms you should watch for.

In a clinical study, the most common side effects of PERJETA + Herceptin + docetaxel were:

  • Diarrhea
  • Hair loss
  • Low levels of white blood cells with or without a fever
  • Nausea
  • Feeling tired
  • Rash
  • Damage to the nerves (numbness, tingling, pain in hands/feet)

If your doctor changes your treatment plan, you may see a change in the side effects.

Patients in the study had less frequent side effects when they stopped taking docetaxel. After stopping docetaxel, all side effects in the PERJETA combination group happened in less than 10% of patients, except for diarrhea, a cold, rash, headache, and feeling tired.

Always report side effects to your healthcare team at any point in your treatment.

You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling
1 (888) 835-2555. You may contact the FDA by visiting www.fda.gov/medwatch or calling 1 (800) FDA-1088.

Please see additional select Important Safety Information throughout, and the accompanying full Prescribing Information including most serious side effects.

What does PERJETA treat?

PERJETA® (pertuzumab) is approved for use in combination with Herceptin® (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.

Important Safety Information

What should I know about side effects with PERJETA?

  • Not all people have serious side effects; however, side effects with PERJETA therapy are common. It is important to know what side effects may happen and what symptoms you should watch for
  • Your doctor may stop treatment if serious side effects happen. Be sure to contact your healthcare team right away if you have questions or are worried about any side effects

What are the most serious side effects?

PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).

  • Your doctor may run tests to monitor your heart function before and during treatment with PERJETA
  • Based on test results your doctor may hold or discontinue treatment with PERJETA

Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects.

  • Birth control should be used while receiving PERJETA and for 7 months after your last dose of PERJETA. If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or stopping PERJETA
  • If you think you may be pregnant, you should contact your healthcare provider immediately
  • If you are exposed to PERJETA during pregnancy, or become pregnant while receiving PERJETA or within 7 months following the last dose of PERJETA in combination with Herceptin, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720 or visiting http://www.motherpregnancyregistry.com and report PERJETA exposure to Genentech at 1-888-835-2555

What are other possible serious side effects?

  • PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA
  • Infusion-related reactions: PERJETA is a medicine that is delivered into a vein through a needle. This process can cause reactions known as infusion-related reactions. The most common infusion-related reactions when receiving PERJETA, Herceptin, and docetaxel were feeling tired, abnormal or altered taste, allergic reactions, muscle pain, and vomiting. The most common infusion-related reactions when receiving PERJETA alone were fever, chills, feeling tired, headache, weakness, allergic reactions, and vomiting
  • Severe allergic reactions: Some people receiving PERJETA may have severe allergic reactions, called hypersensitivity reactions or anaphylaxis. This reaction may be severe, may happen quickly, and may affect many areas of the body

How will my doctor and I know if PERJETA is right for me?

PERJETA has only been shown to work in people with HER2-positive breast cancer. You must have a HER2 test to know if your breast cancer is HER2-positive before receiving an anti-HER2 treatment, such as PERJETA.

What are the most common side effects?

The most common side effects of PERJETA when given with Herceptin and docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are:

  • Diarrhea
  • Hair loss
  • Low levels of white blood cells with or without a fever
  • Nausea
  • Feeling tired
  • Rash
  • Damage to the nerves (numbness, tingling, pain in hands/feet)


You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at (800) FDA-1088 or 
www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see additional select Important Safety Information throughout, and the accompanying full Prescribing Information including most serious side effects.